Bivalirudin versus heparin with primary percutaneous coronary intervention

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Optimal adjunctive therapy for ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI) is debated.
• Real-world data on bivalirudin versus unfractionated heparin (UFH) with or without glycoprotein IIb/IIIa inhibitors (GPI) is limited.

Purpose of the Study:

• To compare the efficacy and safety of bivalirudin versus UFH (with or without GPI) in STEMI patients treated with PPCI.
• To evaluate 30-day mortality, 1-year mortality, stent thrombosis, re-infarction, and major bleeding events.

Main Methods:

• Retrospective analysis of 23,800 STEMI patients from the Swedish national registry (SWEDEHEART) between 2008 and 2014.
• Patients received PPCI with either UFH ± GPI or bivalirudin ± GPI within 12 hours of symptom onset.
• Multivariable regression and propensity score modeling were used to adjust for confounding factors.

Main Results:

• No significant differences in 30-day or 1-year mortality, stent thrombosis, or re-infarction between bivalirudin and UFH groups.
• UFH use was associated with a significantly higher risk of major in-hospital bleeding compared to bivalirudin (adjusted OR 1.62).
• The increased bleeding risk with UFH was attenuated when GPI use was considered in the analysis, suggesting a role for GPI in mitigating bleeding.

Conclusions:

• Bivalirudin offers no significant advantage over UFH in terms of mortality or ischemic events in STEMI patients undergoing PPCI.
• Bivalirudin use was associated with significantly lower rates of major in-hospital bleeding compared to UFH.
• The observed bleeding benefit with bivalirudin may be related to differential GPI use between the treatment groups.